Nasdaq

atai Life Sciences Reports Promising Phase 2a Results for BPL-003 in Alcohol Use Disorder with High Rates of Sustained Abstinence and Well-Defined Safety Profile

Atai Life Sciences announced positive results from a Phase 2a study of BPL-003, a synthetic intranasal treatment for alcohol use disorder (AUD), showing that a single dose combined with relapse ...
Yardbarker

BPL Next Edition to Feature Five Teams in Short One-Month Window

The second season of the Bangladesh Premier League (BPL) will be contested among five teams in a competitive one-month schedule between mid-December and mid-January, BPL Governing Council (GC) ...
Daily Sun

‘Those who can, can do it even in a short time’, Mithun on BPL organisers

Mithun has raised serious concerns over the organisation of the BPL questioning whether it was rushed and warning of its ...
Nasdaq

atai Life Sciences and Beckley Psytech Announce Positive Phase 2b Results for BPL-003 in Treatment-Resistant Depression

Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
Business Wire

First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression

BPL-003 is Beckley Psytech’s patent-protected benzoate formulation of 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery device. The multi-centre, open ...